HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Francesco Cognetti(Apple (Israel)), Alessandra Felici, Alessandra Fabi(Agostino Gemelli University Polyclinic), Paola Papaldo(Cancer Institute (WIA))
Cited by 104
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226